Fig. 2From: Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trialHAE attack patterns in subjects with HAE-C1INH who became pregnant during treatment in the OLE. C1-INH (SC), subcutaneous C1-inhibitor; HAE hereditary angioedema, LMP last menstrual period, OLE open-label extensionBack to article page